Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthroplasty

Trial Profile

A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthroplasty

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SELK 2 (Primary) ; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COURSE
  • Sponsors Tetherex Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2019 As per European Clinical Trials Database this trial has been completed in Bulgaria (2019-11-14)
    • 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
    • 01 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jan 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top